213 related articles for article (PubMed ID: 35284482)
1. Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Who Underwent Surgery for Pancreatic Carcinoma: A Case Report.
Luo X; Ji R; Lu W; Zhu H; Li L; Hu J
Front Surg; 2022; 9():769041. PubMed ID: 35284482
[TBL] [Abstract][Full Text] [Related]
2. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases.
Goto S; Ishikawa JY; Idei M; Iwabuchi M; Namekawa M; Nomura T
Am J Case Rep; 2021 Mar; 22():e929773. PubMed ID: 33723205
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis Presenting With Severe Abdominal Pain Mimicking Acute Peritonitis.
Wang Q; Wu K; Luo X; Dong X; Liu W; Tang Z; Zhang B
Cureus; 2022 Feb; 14(2):e22229. PubMed ID: 35340523
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery.
Chaudhry A; Roels C; Lee J
Can J Diabetes; 2022 Dec; 46(8):843-850. PubMed ID: 36068154
[TBL] [Abstract][Full Text] [Related]
6. Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report.
Fukuda M; Nabeta M; Muta T; Fukami K; Takasu O
Int J Emerg Med; 2020 Jan; 13(1):2. PubMed ID: 31969112
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports.
Khedr A; Hennawi HA; Khan MK; Eissa A; Mir M; Rauf I; Nitesh J; Surani S; Khan SA
World J Clin Cases; 2023 Aug; 11(24):5700-5709. PubMed ID: 37727728
[TBL] [Abstract][Full Text] [Related]
8. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
Sarno MJF; Hernandez DPF; Matulac MO
Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
[TBL] [Abstract][Full Text] [Related]
9. Unsuspected diabetic ketoacidosis after myocardial infarction in a patient treated with SGLT2 inhibitor increased length of stay in the hospital: how can it be prevented? A case report.
Oriot P; Hermans MP; Beauloye C; Rogghe PA; Noel S; Paternotte E
Eur Heart J Case Rep; 2023 Aug; 7(8):ytad336. PubMed ID: 37681058
[TBL] [Abstract][Full Text] [Related]
10. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
Mahfooz RS; Khan MK; Al Hennawi H; Khedr A
Cureus; 2022 Jun; 14(6):e26267. PubMed ID: 35911365
[TBL] [Abstract][Full Text] [Related]
11. Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report.
Matli VVK; Fariduddin MM; Asafo-Agyei KO; Bansal N
Clin Case Rep; 2021 Dec; 9(12):e05144. PubMed ID: 34917366
[TBL] [Abstract][Full Text] [Related]
12. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence.
Mehta PB; Robinson A; Burkhardt D; Rushakoff RJ
Endocr Pract; 2022 Sep; 28(9):884-888. PubMed ID: 35753675
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic diabetic ketoacidosis: A missed diagnosis.
Nasa P; Chaudhary S; Shrivastava PK; Singh A
World J Diabetes; 2021 May; 12(5):514-523. PubMed ID: 33995841
[TBL] [Abstract][Full Text] [Related]
14. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors.
Vitale RJ; Valtis YK; McDonnell ME; Palermo NE; Fisher NDL
AACE Clin Case Rep; 2021; 7(1):10-13. PubMed ID: 33521255
[TBL] [Abstract][Full Text] [Related]
15. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of dapagliflozin-associated diabetic ketosis/ketoacidosis in patients with type 2 diabetes mellitus: A matched case-control study.
Zhao Z; Zhao F; Zhang Y; Hu X; Li J; Tian C; Jin P; Liu D
Diabetes Res Clin Pract; 2023 Feb; 196():110236. PubMed ID: 36610546
[TBL] [Abstract][Full Text] [Related]
17. A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
Patel K; Nair A
Cureus; 2022 Sep; 14(9):e29652. PubMed ID: 36320965
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
19. Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report.
Brown F; McColl T
J Emerg Med; 2018 Jan; 54(1):109-111. PubMed ID: 29157798
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports.
Juneja D; Nasa P; Jain R; Singh O
World J Diabetes; 2023 Aug; 14(8):1314-1322. PubMed ID: 37664476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
